by jtcir-auto | Aug 27, 2024 | Press Releases
– Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol – Potent growth hormone release following macimorelin stimulation – Safety of macimorelin confirmed in the pediatric population...
by jtcir-auto | Aug 13, 2024 | Press Releases
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8 million in cash TORONTO, ONTARIO, Aug. 13, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma...
by jtcir-auto | Aug 13, 2024 | Press Releases
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8 million in cash TORONTO, ONTARIO, Aug. 13, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma...
by jtcir-auto | Aug 6, 2024 | Press Releases
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a...
by jtcir-auto | Aug 6, 2024 | Press Releases
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a...
by jtcir-auto | Jul 16, 2024 | Press Releases
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...